All In Biotech

Drug Trial Radar · NCT07360275

A Study of VCT220 in Participants With Hypertension and Obesity or Overweight

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of VCT220 in Participants With Hypertension and Obesity or Overweight.

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Oct 30, 2026

Study completion Dec 20, 2026

Sponsor

Lead sponsor
Vincentage Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.

Conditions

  • Hypertension

Interventions

  • VCT220 TabletDrug

    Administered orally, with or without food.

  • VCT220 Placebo TabletDrug

    Administered orally, with or without food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in office seated systolic blood pressure (SBP) at Week 20Time frame: From baseline to week 20

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Luhe Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.